Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.46 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 11/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297903 | 0.86 | LIPE (0.46) | SCN9ASCN7AKCNH2LIPEBCHE | |
| SCHEMBL30395340 | 0.86 | LIPE (0.46) | SCN9ASCN7AKCNH2LIPEBCHE | |
| SCHEMBL30700222 | 0.82 | SCN9A (0.42) | SCN9ASCN7AKCNH2LIPEBCHE | |
| SCHEMBL30700300 | 0.81 | SCN9A (0.44) | SCN9ASCN7AKCNH2LIPEBCHE | |
| SCHEMBL30700224 | 0.81 | SCN9A (0.48) | SCN9ASCN7AKCNH2LIPEBCHE | |
| SCHEMBL25255595 | 0.80 | DGAT1 (0.45) | SCN9AKCNH2HCRTR1 | |
| SCHEMBL23091977 | 0.79 | LIPE (0.45) | SCN9ASCN7AKCNH2LIPEBCHE | |
| SCHEMBL25259043 | 0.78 | ACACB (0.39) | SCN9AHCRTR1 | |
| SCHEMBL25295868 | 0.78 | SCN9A (0.43) | SCN9ASCN7AKCNH2 | |
| SCHEMBL29497099 | 0.78 | SCN9A (0.43) | SCN9ASCN7AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | SCN9A 3337/4885SCN7A 4259/4885KCNH2 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.